 |
0 Diseases |  |
8 Trials |
|
8 Trials |  |
181 News |  |
| 123456» |
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) (clinicaltrials.gov) - Feb 28, 2025
P2, N=90, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting
- | patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Journal: HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials. (Pubmed Central) - Feb 25, 2025
This review summarizes recent advances and future potentials, aiming to provide insights into targeted therapy. We hope that this review will provide useful information to physicians in the field.
- ||||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial: Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (clinicaltrials.gov) - Jan 28, 2025
P2, N=372, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Phase classification: PARAMETer: A Window of Opportunity Study of Patritumab Deruxtecan in Patients with Brain Metastases (clinicaltrials.gov) - Dec 18, 2024
P2, N=15, Not yet recruiting, Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP
We hope that this review will provide useful information to physicians in the field. Phase classification: P1 --> P2
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Phase 1/2 study of the HER3-directed antibody-drug conjugate patritumab deruxtecan (MK-1022) as monotherapy in patients with gastrointestinal cancers. (Level 1, West Hall; Poster Bd #: N3) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_977;
P1/2
Clinical Trial Registration Number: NCT06596694. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- |||| Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial: A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) (clinicaltrials.gov) - Dec 13, 2024
P2, N=90, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- | patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Trial completion date, Trial primary completion date: PARAMETer: A Window of Opportunity Study of Patritumab Deruxtecan in Patients with Brain Metastases (clinicaltrials.gov) - Nov 21, 2024
P1, N=15, Not yet recruiting, Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC Trial completion date: Jan 2027 --> Apr 2027 | Trial primary completion date: Jan 2025 --> Apr 2026
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
New P1/2 trial: Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) (clinicaltrials.gov) - Nov 12, 2024
P1/2, N=81, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Biomarker, Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: ICARUS-BREAST01: Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 7, 2024
P2, N=99, Active, not recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial completion date: Jan 2027 --> Apr 2027 | Trial primary completion date: Jan 2025 --> Apr 2026 Recruiting --> Active, not recruiting | N=170 --> 99 | Trial completion date: Jun 2026 --> Apr 2028 | Trial primary completion date: Jan 2024 --> Apr 2025
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Trial primary completion date: HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy (clinicaltrials.gov) - Nov 4, 2024
P3, N=586, Active, not recruiting, Sponsor: Daiichi Sankyo
Recruiting --> Active, not recruiting | N=170 --> 99 | Trial completion date: Jun 2026 --> Apr 2028 | Trial primary completion date: Jan 2024 --> Apr 2025 Trial primary completion date: Aug 2024 --> May 2024
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD), Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
ICARUS-BREAST02: Safety, Tolerability, & Anti-tumor Activity of patritumab deruxtecan (HER3-DXd) monotherapy & combinations in patients (pts) with inoperable advanced breast cancer (ABC) following progression on trastuzumab deruxtecan (T-DXd) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_863;
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Characterization of patritumab deruxtecan activity in breast cancer (BC) patient-derived xenograft (PDX) models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_713;
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC). (Stars at Night 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_177;
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment open: Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (clinicaltrials.gov) - Oct 21, 2024
P1/2, N=130, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial primary completion date: Aug 2024 --> May 2024 Not yet recruiting --> Recruiting
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Oct 17, 2024
P1/2, N=450, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Phase classification: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=450, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Recruiting Phase classification: P2 --> P1/2
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment closed, Metastases: TUXEDO-3: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (clinicaltrials.gov) - Sep 20, 2024
P2, N=63, Active, not recruiting, Sponsor: MedSIR
Phase classification: P2 --> P1/2 Recruiting --> Active, not recruiting
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
New P1/2 trial: Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (clinicaltrials.gov) - Sep 19, 2024
P1/2, N=130, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- || Review, Journal: Novel antibody-drug conjugates based on DXd-ADC technology. (Pubmed Central) - Aug 31, 2024
This review provides a comprehensive assessment of drugs developed with DXd-ADC technology, with a focus on mechanisms of action, pharmacokinetics studies, preclinical data, and clinical outcomes for DS-8201a, U3-1402, DS-1062a, DS-7300a, DS-6157a, and DS-6000a. By integrating existing data, we aim to provide valuable insights into the current therapeutic status and future prospects of these novel agents.
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment closed, Combination therapy, Metastases: U31402-A-U103: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 28, 2024
P1, N=280, Active, not recruiting, Sponsor: Daiichi Sankyo
By integrating existing data, we aim to provide valuable insights into the current therapeutic status and future prospects of these novel agents. Recruiting --> Active, not recruiting
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Trial completion date, Metastases: HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 19, 2024
P2, N=277, Active, not recruiting, Sponsor: Daiichi Sankyo
Recruiting --> Active, not recruiting Trial completion date: Nov 2024 --> Jan 2026
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Review, Journal: Long road towards effective HER3 targeting in breast cancer. (Pubmed Central) - Aug 17, 2024
In this review, we discuss the HER3 role in the pathogenesis of breast cancer and its relevance across all subtypes. We also explore the new anti-HER3 treatment strategies, calling into question the significance of HER3 detection as crucial information in breast cancer treatment.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
HERTHENA-PanTumor01: A global phase 2 trial of HER3-DXd in metastatic solid tumors (Hall 6 - Poster area) - Jul 24, 2024 - Abstract #ESMO2024ESMO_3712;
- Opportunities for ADC Development in 2L NSCLC Leveraging Predictive Biomarkers (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1567;
While T-DXd and HER3-DXd have been tested in HER2 and EGFR mutated cohorts, respectively, Dato-DXd use has not shown to be impacted by any specific biomarker. These results indicate the need to identify predictive biomarkers of response for improved patient population selection.
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD), Tagrisso (osimertinib) / AstraZeneca
Clinical data, Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy. (Pubmed Central) - Jul 22, 2024
P2
The treatment landscape for this heavily pretreated population of patients with EGFRm mNSCLC is fragmented, with no uniformly accepted standard of care. A high unmet need exists for therapeutic options that provide meaningful improvements in clinical benefit.
- | patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Journal: Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA? (Pubmed Central) - Jul 16, 2024
This prioritization by the FDA is grounded in compelling results from the global Phase II HERTHENA-Lung01 trial, wherein HER3-DXd exhibited clinically meaningful efficacy, achieving a median progression-free survival (mPFS) of 5.5 months in patients with heavily treated EGFR-mutated NSCLC. A pivotal question remains: Is a mPFS of 5.5 months sufficient in the context of the evolving first-line landscape observed in the FLAURA-2 and MARIPOSA trials?
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Is knowledge of HER3 as a prospective therapeutic biomarker necessary for pathologists? (Volta) - Jun 28, 2024 - Abstract #ECP2024ECP_668;
In HER2-overexpressing (HER2 3+) tumor tissues, we found a potential correlation between HER3 overexpression and HER2 overexpression. However, whether HER3 expression is associated with disease progression and poor prognosis requires further in-depth analysis.HER3-Dxd has ignited the flames of anti-HER3 therapy, and we need to study HER3 more deeply and extensively in the laboratory.
- || Review, Journal: Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation. (Pubmed Central) - Jun 23, 2024
In breast cancer, several agents are already approved and widely used, including trastuzumab emtansine, T-DXd and SG, and multiple late-stage trials are ongoing...The ETOP IBCSG Partners Foundation are driving strong collaborations in this field and promoting the generation/sharing of databases, repositories and registries to enable greater access data. This will allow the most important research questions to be identified and prioritised, which will ultimately accelerate progress and help to improve patient outcomes.
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment change, Pan tumor: HERTHENA-PanTumor01: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 20, 2024
P2, N=400, Recruiting, Sponsor: Daiichi Sankyo
This will allow the most important research questions to be identified and prioritised, which will ultimately accelerate progress and help to improve patient outcomes. N=120 --> 400
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Trial primary completion date, Metastases: TUXEDO-3: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (clinicaltrials.gov) - May 16, 2024
P2, N=60, Recruiting, Sponsor: MedSIR
N=120 --> 400 Trial primary completion date: Apr 2024 --> Dec 2025
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date, Metastases: U31402-A-U102: HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 14, 2024
P1, N=309, Recruiting, Sponsor: Daiichi Sankyo
Trial primary completion date: Apr 2024 --> Dec 2025 Active, not recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jan 2022 --> Mar 2026
- | patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Journal: Translational Insights and Overall Survival in the U31402-A-U102 Study of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC. (Pubmed Central) - May 2, 2024
In patients with EGFR-mutated NSCLC after EGFR TKI and PBC, HER3-DXd treatment was associated with a clinically meaningful OS. The tumor biomarker characterization comprised the first description of potential mechanisms of resistance to HER3-DXd therapy.
- | patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
New P2 trial, Pan tumor: Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion (clinicaltrials.gov) - Apr 25, 2024
P2, N=30, Not yet recruiting, Sponsor: Samsung Medical Center
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial. (Hall A; Poster Bd #: 389a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3196;
P2
This is the first prospective clinical trial to evaluate the intra-/extracranial efficacy and safety of HER-DXd in pretreated mBC and aNSCLC with BM, and metastatic solid tumors with LMD. If positive, TUXEDO-3 could streamline the introduction of HER3-DXd as a new treatment paradigm for these pts, who currently have very limited therapeutic options.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors. (Hall A; Poster Bd #: 307a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2135;
P2
The primary endpoint for each cohort is ORR by investigator per RECIST version 1.1. Secondary endpoints include safety and tolerability, DOR, DCR, PFS, overall survival, pharmacokinetics, and the correlation between HER3 IHC protein expression and efficacy.
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment change, Metastases: HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 4, 2024
P2, N=277, Active, not recruiting, Sponsor: Daiichi Sankyo
Secondary endpoints include safety and tolerability, DOR, DCR, PFS, overall survival, pharmacokinetics, and the correlation between HER3 IHC protein expression and efficacy. N=420 --> 277
- ||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Enrollment open, Monotherapy, Metastases: ICARUSBREAST02: Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (clinicaltrials.gov) - Mar 28, 2024
P1/2, N=152, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
N=420 --> 277 Not yet recruiting --> Recruiting
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment open, Pan tumor: HERTHENA-PanTumor01: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 13, 2024
P2, N=120, Recruiting, Sponsor: Daiichi Sankyo
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
New P1/2 trial, Monotherapy, Metastases: ICARUSBREAST02: Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (clinicaltrials.gov) - Mar 6, 2024
P1/2, N=152, Not yet recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- DM002 / Doma Pharma, Biocytogen
Preclinical Efficacy of DM002, a bispecific HER3 (Section 2) - Mar 5, 2024 - Abstract #AACR2024AACR_5573;
DM002-BLD1102 also showed strong anti-tumor activity in DM002-vcMMAE resistant PDX models, suggesting the superiority of this new DNA topoisomerase I inhibitor linker/payload over the classical vcMMAE linker/payload. In conclusion, the HER3
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD), R3Mab / Roche, seribantumab (MM-121) / Elevation Oncology
Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers (Section 21) - Mar 5, 2024 - Abstract #AACR2024AACR_5289;
Results from in vitro and in vivo studies highlight the promising therapeutic potential of a seribantumab-based ADC for patients with HER3-expressing cancers. Additional results on the optimization and characterization of HER3-ADC1 will be presented.
- Tagrisso (osimertinib) / AstraZeneca
Enhancing therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: A HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor (Section 30) - Mar 5, 2024 - Abstract #AACR2024AACR_4064;
The innovative HER3 dpADC, leveraging an efficient dual enzymatic site-specific conjugation, exhibited robust anti-tumor efficacy in both in vitro and in vivo settings, surpassing single-agent treatments. Its synergistic mechanism of action presents a promising possibility for developing a more potent and the front-line therapeutic solutions in NSCLC patients who have progressed on standard therapies.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program (Section 44) - Mar 5, 2024 - Abstract #AACR2024AACR_2454;
HER3-DXd is highly active against both HB and RMS models. The high activity of C-ADC for RMS models suggests exquisite sensitivity of RMS models to the DXd payload
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Feb 15, 2024
P2, N=360, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
The high activity of C-ADC for RMS models suggests exquisite sensitivity of RMS models to the DXd payload Trial completion date: Feb 2032 --> Feb 2039 | Trial primary completion date: Feb 2032 --> Feb 2039
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Patritumab deruxtecan (HER3-DXd) in previously treated patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC: Updated safety results from HERTHENA-Lung01 (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_347;
P2
Hematologic and GI TEAEs typically occurred in early TX cycles. No additional safety signals were observed.
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
New P2 trial: Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT (clinicaltrials.gov) - Jan 24, 2024
P2, N=16, Not yet recruiting, Sponsor: The Netherlands Cancer Institute
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Review, Journal: Targeting HER3 to overcome EGFR TKI resistance in NSCLC. (Pubmed Central) - Jan 23, 2024
Preliminary results indicate combining HER3-specific treatments with EGFR TKIs enhances antitumor effects, leading to an increased objective response rate (ORR) and prolonged overall survival (OS) in resistant cases. Embracing HER3-targeting therapies represents a transformative approach against EGFR TKI resistance and emphasizes the importance of further research to optimize patient stratification and understand resistance mechanisms.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). () - Jan 22, 2024 - Abstract #YIR2024YIR_124;
P2
HER3-DXd had an acceptable safety profile, and the data further confirm the clinical activity in MBC in heavy pre-tx MBC across the broad range of HER3 expression levels. Parts B and Z are ongoing and data from this report support the potential entry of HER3-DXd into the therapeutic paradigm in MBC
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD), lumretuzumab (RG7116) / Roche, seribantumab (MM-121) / Elevation Oncology
Review, Journal: The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study. (Pubmed Central) - Jan 17, 2024
Additionally, antibody-drug conjugates (ADCs) like HER3-DXd (patritumab deruxtecan) are new drug candidates that have demonstrated selective delivery of cytotoxic chemicals to NSCLC cells by exploiting HER3's widespread expression, minimizing cytotoxicity. This review aims to evaluate the efficacy of current HER3 therapeutics in development and their therapeutic potential in NSCLC, incorporating evidence from clinical trials.
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment open, Metastases: TUXEDO-3: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (clinicaltrials.gov) - Jan 16, 2024
P2, N=60, Recruiting, Sponsor: MedSIR
This review aims to evaluate the efficacy of current HER3 therapeutics in development and their therapeutic potential in NSCLC, incorporating evidence from clinical trials. Not yet recruiting --> Recruiting